BACKGROUND Brucellosis is one of the most important infection of diseases. Due to its large period of treatment and survival ability of bacteria inside the macrophages, relapse of this disease is the main challenge, especially, after the treatment. OBJECTIVE The current study was carried out to evaluate the antibacterial effect of solid lipid nanoparticles loaded with doxycycline on the Brucella melitensis in in vivo conditions. METHODS The double emulsion synthesized doxycycline-encapsulated solid lipid nanoparticles (DOX-SLN) was characterized using DLS and FE-SEM. The efficacy of the DOX-SLN on the acute and chronic Wistar rat infected brucellosis was investigated. The pathological assessments were made on the spleen and liver in the treated rates. RESULTS The in vivo experimental results demonstrated that the treated rats with DOX-SLN had significantly decreased the B. melitensis CFUs in their spleen and liver compared to that of the treated rates with free doxycycline and untreated ones. The pathologic results indicate that the improvement trend of spleen and liver tissues in rats treated by DOX-SLN was satisfactory. CONCLUSION According to in vivo results, the DOX-SLN has better effects on the treatment of chronic brucellosis. Therefore, DOX-SLN is recommended to treat the brucellosis and avoid its relapse.

中文翻译：

---

多西环素包裹的固体脂质纳米颗粒增强了治疗慢性布鲁氏菌病和预防其复发的抗菌潜力：体内研究。

背景技术布鲁氏菌病是最重要的传染病之一。由于其较长的治疗周期和巨噬细胞内细菌的存活能力，这种疾病的复发是主要挑战，特别是在治疗后。目的：本研究旨在评价负载强力霉素的固体脂质纳米粒在体内条件下对澳洲布鲁氏菌的抗菌作用。方法采用DLS和FE-SEM对双乳合成的多西环素包裹固体脂质纳米粒（DOX-SLN）进行表征。研究了 DOX-SLN 对急性和慢性 Wistar 大鼠感染的布鲁氏菌病的疗效。在治疗率中对脾脏和肝脏进行病理学评估。结果 体内实验结果表明，与游离强力霉素和未处理大鼠相比，DOX-SLN 处理的大鼠脾脏和肝脏中的 B. melitensis CFUs 显着降低。病理结果表明DOX-SLN治疗大鼠脾脏和肝脏组织的改善趋势令人满意。结论 根据体内试验结果，DOX-SLN对慢性布鲁氏菌病的治疗效果较好。因此，建议使用 DOX-SLN 治疗布鲁氏菌病并避免其复发。结论 根据体内试验结果，DOX-SLN对慢性布鲁氏菌病的治疗效果较好。因此，建议使用 DOX-SLN 治疗布鲁氏菌病并避免其复发。结论 根据体内试验结果，DOX-SLN对慢性布鲁氏菌病的治疗效果较好。因此，建议使用 DOX-SLN 治疗布鲁氏菌病并避免其复发。